I think the ramifications of the criminal investigation into Veneto caused a lot on internal and external harm to the MSO. And this was foreseeable even before Generex completed the acquisition. I believe the main thing Generex needs to show in the 10K is shareholder equity and assets under management. Revenue was in steep decline for the MSO. Joe did say a year ago that he expected quick revenue gain for Excellagen, but that was tempered a bit in the last CC when it was pointed out that product is initially given out for promotional purposes. So, I think it’s more about filing a K that shows the company meets national listing criteria albeit without the necessary pps (for now).